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Non-invasive cardiac imaging for 
evaluation of cardiotoxicity in cancer 
patients - early detection and follow-up
and early identification of cardiac toxicity during and after treatment. 
Non-invasive cardiac imaging techniques have been widely used for 
identification of patients with pre-clinical and clinical cardiotoxicity 
as well as for follow-up. Until recently, these modalities were pre-
dominantly limited to echocardiography and radioisotope-based 
nuclear imaging, but cardiac magnetic resonance has emerged and 
appears to may have unique advantages over traditional techniques. 
Coronary computed tomography, likely due to its relative lack of 
physiologic information, need for ionising radiation and nephrotoxic 
contrast, has thus far not been widely investigated in this patient 
population.
NUCLEAR CARDIOLOGY
Identifying patients at risk for the development of cardiotoxicity is 
paramount to the identification, early treatment and prevention of 
clinical forms of cardiomyopathy. Radionuclide-based techniques, 
through equilibrium radionuclide angiocardiography (ERNA), 
gained favour in the late 1970s as a reliable method to quantify left 
ventricular ejection fraction (LVEF). More recently, interest has 
grown in the use of molecular based imaging with targeted agents 
such as Iodine-123 MIBG for neuronal imaging, Indium-111 anti-
miosin for myocardial necrosis and Tc-99m–labelled annexin V for 
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BACKGROUND
Cardiotoxicity of chemotherapeutic agents has become an impor-
tant clinical entity faced by oncologists and cardiologists when 
treating patients with cancer. It is most commonly caused by 
anthracycline-based therapies (doxorubicin, daunorubicin) as well 
as the newer monoclonocal antibodies or small molecule tyrosine 
kinase inhibitors, most notably trastuzumab (Herceptin). Although 
the mechanism of cardiotoxicity differs considerably between anth-
racyclines and trastuzumab, the net result is generally ventricular 
dysfunction and heart failure. Other manifestations of cardiotoxicity 
include myocardial ischaemia, arrhythmias, hypertension, pericardial 
disease, and thromboembolic disease.
The anthracycline agents, such as doxorubicin, are effective agents 
used in the treatment of breast cancer, ovarian cancer, leukaemia, 
lymphoma, neuroblastoma, sarcoma and gastric cancer. The mecha-
nism of anthracycline cardiotoxicity is complex but a primary medi-
ator is thought to be oxidative damage to myocytes through free 
radical formation. This may lead to membrane disruption, extensive 
cellular dysfunction and ultimately myocyte death. There is a dose-
response relationship between dose of doxorubicin and cardio-
toxicity with rates of congestive heart failure rising rapidly at mean 
cumulative doses above 550mg/m2(1). Nevertheless, there is con-
siderable variability among patients receiving doxorubicin, which 
highlights the need for reliable imaging techniques for monitoring 
Cardiotoxicity is an increasingly important clinical entity that 
occurs as a result of untoward, and incompletely understood, 
effects on cardiac function. It is primarily caused by the 
anthracycline agents (doxorubicin, daunorubicin) but has also 
been observed with monoclonal antibody agents such as 
trastuzumab and small molecule tyrosine kinase inhibitors. 
The most feared net result of these agents is left ventricular 
(LV) dysfunction resulting in symptomatic congestive heart 
failure (CHF). Other manifestations can include arrhythmias, 
pericardial constriction, valvulopathy and hypertension. 
Standard cardiac imaging techniques have largely focused on 
LV ejection fraction (LVEF) quantifi cation. Contemporary 
cardiac imaging technologies now exist that are capable of 
evaluating for and detecting earlier stages of cardiotoxicity, 
including those which occur prior to changes in LVEF. Thera-
peutic algorithms have been devised to tailor chemothera-
peutic regimens based on these results and have resulted in a 
dramatically reduced incidence of overt CHF. 
SAHeart 2012; 9:264-273
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imaging cell death or apoptosis.(2) Lastly, targeted cardiac imaging 
with Positron Emission Tomography (PET) may be able to detect 
early cell death due to doxorubicin.
Equilibrium Radionuclide Angiocardiography (ERNA)
ERNA, also known as a MUGA scan (multi-gated acquisition), 
involves tagging a patient’s red blood cells with a radionuclide agent, 
technetium-99m, using an in-vivo or in-vitro technique. The tagged 
red blood cells are typically re-injected followed by image acquisi-
tion 15-30 minutes later depending on technique. Importantly, 
image acquisition is gated to the patient’s cardiac rhythm at rest via 
an ECG monitor and 300-600 heartbeats are obtained on average 
over 5-10 minutes. A minimum of 16 frames should be acquired 
per cardiac cycle, but 24 to 32 frames provide better temporal 
resolution and are preferred for LVEF calculation. The patient is 
imaged in 3 standardised views: left anterior oblique (LAO), 
anterior and left lateral (Figure 1). By drawing regions of interest 
(ROI) around the left ventricle in the LAO view, absolute ventricular 
volumes can be computed by a count-based algorithm at end-
systole and end-diastole from which background counts are 
subtracted (arbitrarily placed ROI lateral to the left ventricle) 
(Figure 2) to derive a volumetric-time curve (Figure 3). Additional 
parameters including diastolic function, peak and mean filling and 
emptying rates can also be derived, most of which appear to be 
equally accurate in predicting early cardiotoxicity.(3) The inherent 
advantages of this technique are its non-invasive nature, high 
reproducibility and the fact that measurements of LV volume and 
function do not rely on geometric assumptions regarding LV shape 
but rather on total LV counts. Limitations include the need to weigh 
the individual’s risk of total effective radiation dose versus net 
clinical benefit, difficulty ensuring optimal image acquisition angles 
and problematic ECG gating in the setting of baseline arrhythmias 
such as atrial fibrillation. 
The single largest study involving monitoring for cardiotoxicity 
involved serial ERNA or Single Photon Emission Computed 
Tomography (SPECT) imaging in 1 487 patients receiving doxo-
rubicin.(4) Using this method of screening, 19% of patients were 
deemed to be at high risk for developing cardiotoxicity (defined as 
a baseline LVEF <50%, a drop in LVEF by ≥10% to a value <50% or 
cumulative doxorubicin doses ≥450 mg/m2). Interestingly, clinical 
CHF improved in 87% of patients who were given routine therapy 
with digitalis, diuretics and/or vasodilators. Based on these high risk 
features, standard criteria were developed to aid in the manage-
ment of screening for subclinical doxorubicin-associated cardio-
toxicity with ERNA (Table 1). The implementation of these guide-
lines resulted in a reduction in the incidence of heart failure due to 
cardiotoxicity. This was primarily due to the fact that these 
guidelines intended purpose was to allow the maximum dose of 
doxorubicin to be administered based on an individually determined 
threshold for subclinical cardiotoxicity.
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FIGURE 1: Labelled equilibrium radionuclide angiocardiography showing left anterior oblique view (A), anterior view (B) and left lateral view (C). 
LV = left ventricle. RV = right ventricle. Ao = ascending aorta. AoA = aortic arch. Dao = descending aort. PA = pulmonary artery.
FIGURE 2: Regions of interest drawn around the left ventricular 
blood pool cavity at end-diastole (ED, red arrow) and end-systole 
(ES, yellow arrow). The blue arrow represents the region of interest 
drawn inferior and lateral to the LV for the purposes of correction 
of background counts.
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Based on the guidelines above, a more recent study demonstrated 
that 15% of patients receiving doxorubicin were deemed at high 
risk for CHF at some point during their therapy.(5) Furthermore, 
implementation of ERNA screening led to early discontinuation of 
treatment in 13% of patients due to criteria for cardiotoxicity, the 
majority of whom were asymptomatic. The same study found a net 
cost effectiveness of screening relative to estimated costs for the 
treatment of symptomatic CHF. This highlights the importance of 
routine screening, as many patients will demonstrate cardiotoxicity 
via a reduction in LVEF in the absence of overt heart failure 
symptoms.
While the accuracy and reproducibility of ERNA-based methods of 
LVEF quantification are established, the sensitivity and test charac-
teristics for the prediction of CHF is suboptimal.(6) An abnormal 
LVEF at rest (<=45%) had a sensitivity of 53% and a specificity of 
75% for detecting patients at moderate or high risk of developing 
CHF when compared to the gold standard of endomyocardial 
biopsy. The addition of exercise LVEF increased the sensitivity of 
detection of moderate or high-risk patients to 89% but lowered the 
specificity to 41%. Therefore, single resting LVEF measurements are 
not likely to possess the sensitivity required for widespread use as 
screening tests.
Despite certain pitfalls and concerns related to using changes in 
LVEF for prediction of subsequent cardiac dysfunction, ERNA 
continues to be a simple, effective and readily available approach 
for preventing cardiac morbidity and mortality.
Molecular imaging
Iodine-123–labelled metaiodobenzylguanidine (I-123 MIBG) is 
iodine labelled lab tracer that shares adrenergic neuroreceptor 
uptake storage and release mechanisms wino epinephrine. Myo-
cardial uptake of I-123 MIBG reflects neuronal integrity and its 
release reflects adrenergic function.(7) There is animal and human 
evidence that reduced I-123 MIBG uptake occurs in doxorubicin 
cardiotoxicity, however this usually parallels changes in LV systolic 
function.(2) 
Indium-111 antimyosin (In-111 antimyosin) is a tracer that was 
developed for imaging of myocardial necrosis in a diverse set of 
cardiac pathologies such as myocarditis, transplant rejection and 
doxorubicin cardiotoxicity. In-111 antimyosin uptake occurs prior 
to changes in LV systolic function, however no long term studies 
exist and the specificity of this tracer for the prediction of 
cardiotoxicity is poor.(9,10) Lastly, tracer availability, expense, and 
technical challenges limit its widespread clinical and research 
applicability.
FIGURE 3: Count/volume-time curve derived from obtaining 
multiple count measurements at distinct points in the cardiac 
cycle. The solid green line represents the moment of highest 
counts (end diastole) and the dotted blue line represents end-
systole. Due to the directly proportional relationship between 
counts and volumes, LV ejection fraction can be automatically 
computed. 
Seconds
12 000
10 000
8 000
6 000
4 000
2 000
0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
TABLE 1: Guidelines for monitoring patients receiving doxorubicin. 
Adapted from Schwartz RG, et al.(6)
LVEF = left ventricular ejection fraction. ECG = electrocardiogram.
Guidelines for monitoring patients receiving doxorubicin
Perform baseline radionuclide angiocardiography at rest for calculation of left 
ventricular ejection fraction (LVEF) prior to administration of 100mg/m2 of 
doxorubicin.
Subsequent studies are performed at least 3 weeks after the indicated total 
cumulative doses have been given, before consideration of the next dose.
Patients with normal baseline LVEF (≥50%)
Perform a second study after 250-350mg/m2.
Repeat study after 400mg/m2 in patients with known heart disease, radiation 
exposure, abnormal ECG results, or cyclophosphamide therapy; or after 
450mg/m2 in the absence of any of these risk factors.
Discontinue doxorubicin therapy once functional criteria for cardiotoxicity 
develop, e.g. absolute decrease in LVEF ≥10% associated with a decline to a 
level ≤50%.
Patients with abnormal baseline LVEF (<50%)
Doxorubicin therapy should not be initiated with baseline LVEF ≤30%.
In patients with LVEF >30% and <50% sequential studies should be obtained 
prior to each dose. 
Discontinue doxorubicin with cardiotoxicity: absolute decrease in LVEF ≥10% 
and/or fi nal LVEF ≤30%.
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Technetium-99m–labelled annexin V, an exciting radionuclide agent 
for imaging cell death, has been successfully evaluated in the 
detection of doxorubicin cardiotoxicity.(11) However, limited human 
experience means the future role for the precise evaluation, timing 
and detection of cardiotoxicity by this agent is undetermined.
Lastly, Herceptin (trastuzumab) labelled with Indium-111 (In-111-
TZ) has been used to image metastatic breast cancer expressing 
the human epidermal growth factor receptor 2 (HER2) receptor.(12) 
A report of 20 patients with metastatic breast cancer expressing 
the HER-2 receptor demonstrated that 35% of patients had evi-
dence of myocardial In-111-TZ uptake prior to administration of 
any chemotherapy and 86% of those patients with tracer uptake 
developed clinical heart failure, whereas none of the patients 
without uptake had adverse cardiac event.(13)
These findings demonstrate the unique potential for targeted 
molecular imaging in providing useful therapeutic and prognostic 
information in patients being treated with potentially cardiotoxic 
agents. Larger studies are needed to confirm these findings and 
determine the effects of trastuzumab on cardiac events.
Cardiac PET imaging
The role of cardiac PET imaging has not been extensively investi-
gated for the detection of cardiotoxicity. C-11 acetoacetate and 
C-11 acetate, markers of myocardial perfusion and oxidative meta-
bolism, have been used and the former appears to be a more 
sensitive marker for the detection of cardiotoxicity and may be a 
promising alternative to ventriculography.(8) Cardiac PET is mostly 
used with fluorine-18-fluorodeoxyglucose (F-18 FDG) for the eva-
luation of malignant pericardial involvement, cardiac lymphoma 
staging and has largely focused on the diagnosis of metastatic lesions 
and response to chemotherapy in a wide range of malignancies.
ECHOCARDIOGRAPHY
Since the report that demonstrated a benefit of adjustment of 
doxorubicin therapy based on serial monitoring of LVEF employed 
ERNA,(6) this modality remains a mainstay of LV function assessment 
during cancer therapy. Nevertheless, echocardiography is preferred 
in many centres because of lack of radiation exposure, easier 
availability as well as the added benefit of assessing valvular dys-
function and pericardial disease which are typical sequelae of radi-
ation therapy that is often used in combination with cardiotoxic 
chemotherapy.(14)
Two-dimensional (2D) echocardiographic assessment 
The Cardiology Committee of the Children’s Cancer Study Group 
reported that, as was demonstrated with ERNA-derived LVEF 
criteria, a protocol of chemotherapy regimen adjustment according 
to echocardiographic LVEF criteria does reduce heart failure rates, 
in this case in a paediatric population.(15) A strategy of anthracyclines 
discontinuation for reductions in fractional shortening (FS) to <30% 
resulted in a very low incidence of congestive heart failure of 0.4% 
(3 of 766 patients). This is in contrast to the 20 patients that would 
have been expected by historical cardiotoxicity rates in the absence 
of cardiac monitoring.
Traditionally, however, 2D-based echocardiographic methods have 
been considered less accurate than ERNA in the assessment of 
LVEF. The drawback of 2D-echocardiography stems from inherent 
limitations in how ejection fraction is mathematically extrapolated. 
Echocardiographic LV volumes are best estimated using the 
modified Simpson (or disk summation) method. In the modified 
Simpson method, orthogonal apical four- and two-chamber views 
are obtained. The endocardial borders are traced either auto-
matically or manually and the LV is divided into disks of equal 
heights. The volume of each cylinder is calculated from the four- 
and two-chamber image derived diameters and then the volumes 
are summed to give the LV volume. This method is highly dependent 
on reliable visualisation of the endocardial borders and absence of 
foreshortening. In addition this method extrapolates a volume from 
two 2-dimensional slices by assuming that the LV is symmetric 
which is frequently not the case.(16) Only a handful of early studies 
have directly compared 2D-echocardiography with radionuclide 
imaging in the detection of cardiotoxicity. The first of these was a 
study comparing radionuclide imaging to echocardiography in 37 
patients receiving doxorubicin or daunorubicin and found that 
echocardiography was less sensitive and specific.(17) In another study 
comparing radionuclide based assessment to early echocardiography 
in those receiving doxorubicin who had received endomyocardial 
biopsy and right heart catheterisation also found that echo-
cardiography was less sensitive.(6) Both studies, however, were 
limited to M-mode based fractional shortening assessment, which 
cannot be extrapolated to modern 2D imaging technology. 
More recent studies have demonstrated that despite good corre-
lation between LVEF by echocardiography versus LVEF by ERNA 
(r = 0.81), intra- and inter-observer reproducibility is better for 
ERNA.(18) As a result, the authors proposed that ERNA should be 
the method of choice when precise reproducibility is important in 
patient management. Since relatively modest falls in EF by 10% or 
to a level less than 50% may trigger a discontinuation of potentially 
life-saving cancer therapy, precision should be considered a priority 
in monitoring for cardiotoxicity. When 2D-echocardiography and 
ERNA were utilised routinely before and after anthracycline use in 
a paediatric population, ERNA detected a significantly higher rate of 
cardiac dysfunction, and only ERNA detected diastolic dysfunction.(19)
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dimensions. Through acquisition of pyramidal-shaped volumes, 
3D-echocardiography largely avoids this problem. By allowing 
precise manipulation of imaging planes to the long axis and short 
axis of the LV, 3D imaging also avoids pitfalls of foreshortening 
and oblique imaging.(23) 
Current real-time 3D technology generally uses matrix phased-
array technology, which consists of multiple (>3 000) piezoelectric 
imaging elements arranged in a grid. LV assessment uses apical 
wide-angle acquisition with or without ECG gating and breath-
holding. Acquired pyramidal data can then be cropped to view 
cardiac structures including optimised conventional 2D planes. To 
calculate LV volumes and ejection fraction, the user marks the 
mitral valve annulus and apex in multiple planes. Semi-automated 
3D tracings of the endocardial border enable volumetric and 
functional calculations. If the LV is particularly asymmetric, a disc 
summation method using multiple short axis slices can be used 
instead.(24)
3D-echocardiographic assessment of LVEF has been found to be 
superior to 2D and comparable to CMR based techniques. A study 
recently performed 2D-echocardiography, cardiac MR and real 
time 3D-echocardiography in 50 patients with cardiovascular 
disease. Real-time 3D measurements of end-diastolic volume, end-
systolic volume and ejection fraction correlated highly with meas-
urements by cardiac MR with a correlation coefficient of 0.93 for 
ejection fraction. 2D-echo measurements correlated less well 
with cardiac MR with a correlation of 0.86 for ejection fraction. 
Furthermore, the intra-observer, inter-observer and inter-exami-
nation variability of 3D based measurements was small and lower 
than 2D.(25) 
Other groups have compared real-time 3D assessment of LVEF to 
cardiac MR and have similarly found consistent results.(20,26-29) In 
most cases, 3D measurements of LV volume have been found to 
slightly underestimate LV volumes when compared to CMR. This 
can be explained by the limited spatial resolution of certain 3D-echo 
datasets (Figure 4), as well as difficulties in differentiating compacted 
myocardium from non-compacted trabeculae. Recommendations 
for tracing the endocardial border on 3D-echo to include trabeculae 
in the LV cavity have been proposed.(27) Since precision is critical to 
use of any imaging modality for serial assessment to guide thera-
peutic decisions and limits in the precision of LVEF assessment are 
the primary drawback of 2D-echo when compared to radionuclide 
imaging, 3D volumetric assessment of EF holds great promise as a 
safe, accessible and reliable technique for monitoring cardiotoxicity 
of cancer therapy. 
Lastly, the most comprehensive study from a multi-modality per-
spective examined ERNA, 2D-echo, 3D-echo and cardiac magnetic 
resonance imaging (CMR) for the evaluation of cardiac function 
during trastuzumab therapy after doxorubicin. All patients received 
serial imaging using all 4 modalities at baseline, 6 and 12 months 
after beginning trastuzumab. They found a weak correlation 
between 2D-echo and CMR (r = 0.31 at baseline and r = 0.42 at 
12mo), whereas the correlation for both 3D-echo and ERNA 
versus CMR were strong (r = 0.91 at baseline; r = 0.90 at 12 
months’, respectively.(20) 
A retrospective review of 217 consecutive patients who underwent 
pre-chemotherapy echocardiograms revealed relevant cardiac 
abnormalities that would not have been identified by radionuclide 
imaging such as aortic stenosis or moderate mitral regurgitation in 
7.4% of patients, and led to a change of chemotherapy in 2.8%.(21) 
Based on this finding, this group proposed that echocardiography is 
more useful than radionuclide imaging; however, studies which 
demonstrate that the identification of these incidental findings leads 
to improved outcomes would be needed to support a change in 
practice.
Current guidelines of practice permit either 2D-echocardiography 
or radionuclide imaging for the evaluation of cardiotoxicity. One of 
the only committee-based guidelines came from the Cardiology 
Committee of the Children’s Cancer Study Group. The authors of 
those guidelines stated that either imaging approach could be 
selected based on the characteristics of the patient and the 
availability at the institution. For example, echocardiography works 
particularly well in children, who have excellent acoustic windows, 
and who may not be able to tolerate the relative lack of movement 
during ERNA acquisition and for whom minimisation of excess 
radiation exposure is a top priority. It should be emphasised, how-
ever, that regardless of the modality used, it should be used con-
sistently throughout serial monitoring.(15) 
3D-echocardiographic assessment 
3D-echocardiography is an emerging ultrasound technology that is 
not yet universally available in all cardiac ultrasound laboratories. 
However, it is being rapidly adopted as technology advancements 
have made routine use more practical in clinical settings. It has not 
been studied specifically in relation to monitoring cardiotoxicity of 
cancer therapy, but 3D-echocardiography has been shown to be 
the most reliable ultrasound based technique for LV function 
assessment.(22) The main obstacle to accurate assessment of LV 
function by 2D-echocardiography is the need to make assumptions 
about 3 dimensional ventricular shapes based on images in 2 
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Other echocardiographic parameters
Left ventricular ejection fraction assessment is an unsatisfactory 
endpoint for monitoring cardiotoxicity because it identifies patients 
too late to prevent significant morbidity in some. Several alternative 
markers of pre-clinical cardiac dysfunction have been explored such 
as diastolic function, stress echocardiography and more recently, 
myocardial strain imaging. 
Diastolic dysfunction
Various studies have explored changes in diastolic function before 
and after anthracycline exposure(30-34) in an attempt to provide a 
measure of risk. In patients receiving doxorubicin, the isovolumic 
relaxation period prolonged, early peak flow (E) was reduced and 
the ratio of early peak flow velocity to atrial peak flow velocity 
(E/A) also decreased significantly demonstrating worsening of 
diastolic indices when compared with age and sex matched controls 
or when compared with pre-treatment states.(31) It has also been 
found that a 37% increase in isovolumic relaxation time using 
Doppler echocardiography after doxorubicin was 78% sensitive 
and 88% specific for predicting a future drop in systolic function.(30)
Baseline abnormal E/A ratio prior to treatment has also been 
associated with later development of cardiotoxicity.(32) These 
findings, however, are inconsistent. Another study found a relation-
ship between anthracycline dose and poorer diastolic function 
indexes, but failed to find that diastolic dysfunction was helpful in 
predicting subsequent systolic dysfunction.(33) As a result, monitoring 
of diastolic function using transmitral flow velocities has failed to 
become an important component of cardiotoxicity monitoring. 
Contractile reserve
Dobutamine stress echocardiography has been used in research 
settings to assess myocardial reserve in adults treated with anthra-
cyclines, but worsening of systolic augmentation after anthracyclines 
has not been consistently found.(32,35) One study, however, did note 
a smaller rise in peak E and fall in E/A ratio during dobutamine 
administration after anthracycline therapy and concluded that these 
findings represent the unmasking of early stage anthracycline 
cardiotoxicity.(36)
Evaluation of contractile reserve by stress testing has also been 
investigated, specifically in a paediatric population. In children late 
onset cardiotoxicity is more common and techniques to identify 
those survivors of childhood cancer at risk for later clinical heart 
failure are needed.(37,38) Exercise stress testing has been studied 
repeatedly in those treated with anthracyclines as children and was 
found to be helpful in identifying subclinical cardiotoxicity.(35,39,40) 
One study showed that children treated with anthracyclines had 
lower increases in cardiac index for similar levels of exercise when 
compared to age match controls.(39) More recently, it was shown 
that survivors of childhood cancer had lower percent thickening at 
end systole and reduced end-systolic wall stress after exercise 
compared to healthy controls.(35) At this time, however, a role for 
stress echocardiography in the routine clinical evaluation of patients 
treated with anthracyclines has not been defined.
Myocardial strain imaging
The echocardiographic technique with the greatest potential to 
improve our ability to identify those with early cardiotoxicity after 
treatment is strain imaging. Strain imaging previously used tissue-
Doppler techniques; however, due to several criticisms, particularly 
in relation to angle dependency, noise interference and substantial 
intra- and inter-observer variability, Speckle-tracking Echocardio-
graphy (STE) has emerged as an alternative technique in recent 
years.(41) With speckle tracking, natural acoustic reflectors within 
the myocardium also known as “speckles” are tracked from frame 
to frame to determine deformation (strain) and the speed of 
deformation (strain rate) (Figure 5). For the LV, 3 normal strain 
components are used to describe normal deformation (longitudinal, 
circumferential and radial) (Figure 6). 
Several investigations have been published examining myocardial 
strain imaging after doxorubicin or trastuzumab treatment. In a 
murine model of cardiotoxicity, while LVEF and FS began to decline 
around day 5, strain rate imaging fell significantly as early as day 2 
indicating the ability to detect earlier stages of dysfunctional 
myocardial mechanics.(42) In a similar study in humans changes in 
radial strain appeared earlier and were more pronounced than in 
FIGURE 4: Effects of 3D-echo image quality on endocardial 
visualisation. These examples of short-axis planes extracted from 
real time 3D-echo datasets demonstrate how spatial resolution 
may affect the perception of endocardial boundaries. In 1 patient 
(left), endocardial trabeculae can be well visualized and clearly 
differentiated from the myocardium and thus appropriately 
included in the LV cavity. In contrast, in the second patient (right), 
the spatial resolution of the real time 3D-echo image is not 
suffi cient to provide this kind of detail and is likely to result in 
erroneous exclusion of the trabeculae from the LV cavity. 
Reprinted with permission from.(27) 
Patient 1 Patient 2
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Global and regional LV longitudinal and radial strain were signifi-
cantly reduced in the absence of a significant change in LVEF in the 
first week after anthracycline therapy.(44) In a paediatric popula-
tion receiving anthracyclines, early changes in LV longitudinal peak 
systolic strain occurred and correlated significantly with a subsequent 
change in EF.(45) Regarding strain imaging after treatment with 
trastuzumab patients who had received anthracyclines at least 6 
months prior to trastuzumab still had a significant difference in 
mean 2D longitudinal strain rate at 3 to 12 months when compared 
to 0 to 3 months.(46) 
Collectively these data suggest that myocardial strain imaging 
parameters will be useful adjuncts to echocardiographic assessment 
of patients treated with cardiotoxic chemotherapy. As 3D speckle 
tracking becomes more prevalent, 3D strain assessments may 
further advance our ability to detect subclinical affects of cancer 
therapy on cardiac function.  
CARDIAC MAGNETIC RESONANCE (CMR)
Cardiac magnetic resonance (CMR) is less frequently used as a 
non-invasive cardiac imaging tool to detect cardiotoxicity probably 
the longitudinal direction after 6 cycles of pegylated liposomal 
doxorubicin.(43) Radial deformation, a measure of myocardial wall 
thickening, may arise as a result of cardiotoxic damage to all 3 layers 
of the myocardium, unlike in ischaemic heart disease. 
FIGURE 5: Strain imaging in a normal subject. Examples of tissue Doppler imaging velocity, strain rate and strain curves for a cardiac cycle from a 
subject with normal cardiac function. L = length. V = velocity. Reprinted with permission from.(27)
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FIGURE 6: Myocardial fi bre orientation and principal vectors of 
left ventricular strain. Echocardiographic application of strain 
imaging has assessed longitudinal strain from apical windows and 
radial, circumferential and rotational strain from parasternal 
windows. Reprinted with permission from.(60)
Longitudinal
Radial and 
circumferential
Rotational
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because of the ubiquity of radionuclide and echocardiographic 
technologies. Nevertheless, due to its good temporal and spatial 
resolution, CMR is considered the gold standard for the assess-
ment of LV function;(47) is exquisitely sensitive for the detection of 
unrecognised subendocardial myocardial infarctions by SPECT 
perfusion imaging;(48) and through T2-weighted imaging, has the 
unique potential to detect myocardial oedema.(49) Perhaps for these 
reasons, the American College of Cardiology & American Heart 
Association Guidelines have recognised CMR as a viable modality 
for the screening of cardiotoxicity.(50) 
The utility of CMR for the assessment of trastuzumab cardiotoxicity 
was investigated in 10 breast cancer patients with suspected 
trastuzumab-induced cardiomyopathy.(51) Remarkably, late gado-
linium enhancement (LGE), a marker of intramyocardial fibrosis and 
inflammation, was present in the subepicardial segments of the 
lateral walls of all 10 patients. Despite the recovery of LV function 
with appropriate therapy in 6 of these patients, the LGE persisted 
in all patients up to 6 months suggesting persistent myocardial 
injury. A follow-up report of 36 patients with trastuzumab-induced 
cardiomyopathy from the same group demonstrated that 94% of 
patients had the same subepicardial lateral wall LGE, a potentially 
pathognomonic sign for trastuzumab cardiotoxicity (Figure 7). 
Gadolinium-enhanced T1 mapping is a novel CMR-based technique 
that allows detection of diffuse myocardial fibrosis that may not be 
readily visible on LGE images.(52) To date, T1 mapping has been 
used in 4 studies of doxorubicin cardiotoxicity (3 animal, 1 human) 
and all have shown correlation to its histopathologic features.(53-56) 
Collectively, an absence of change of T1 values appears to indicate 
protection from the development of cardiotoxicity. Conversely, in 
those subjects with the highest increase in gadolinium-enhanced T1 
values, an association with the development of congestive heart 
failure was found. Clearly larger studies with longer patient follow-
up are required but for now T1 mapping for the detection of 
doxorubicin cardiomyopathy appears to hold much promise.
CARDIAC COMPUTED TOMOGRAPHY 
ANGIOGRAPHY (CCTA)
Cardiac computed tomography angiography (CCTA) has emerged 
as a powerful tool for the non-invasive evaluation of the coronary 
arteries and an alternative to invasive diagnostic angiography. To 
our knowledge, there are no reports of CCTA for the evaluation of 
cardiotoxicity-induced subclinical LV systolic dysfunction. 
However, there are data emerging on using CCTA for coronary 
artery evaluation in patients formerly treated for childhood malig-
nancies, such as Hodgkin’s lymphoma.(57) In this young asymptomatic 
patient cohort with a mean age of 20 years (range 6 to 43 years), 
CCTA detected coronary artery disease in 16% of patients with 2 
cases of severe, obstructive coronary artery plaque. In a smaller 
series of 9 patients formerly treated for Hodgkin’s lymphoma, 8 out 
of 9 had coronary disease and coronary artery calcium scores 
higher than their aged matched peers. Of these asymptomatic 
indidivuals 2 out of 9 underwent revascularisation with coronary 
bypass surgery or angioplasty.(58) Larger prospective studies are 
required to better define the role of coronary CT angiography and 
calcium scoring and to ideally establish an algorithm for the 
evaluation and treatment of such patients.
CONCLUSIONS
Since the initial reports of doxorubicin cardiotoxicity nearly 40 
years ago, multi-modality screening cardiovascular imaging tech-
niques have changed dramatically.(59) Since the initial establishment 
of LV ejection fraction-based techniques such as ERNA, there have 
been continued advances in the fields of radionuclide imaging, 
echocardiography, magnetic resonance and computed tomography. 
Ideally, cardiovascular medicine specialists need to interface in a 
multi-disciplinary approach to ensure optimal patient outcomes. 
Much work has been completed, yet further investigation remains 
for cardiac imaging techniques to provide refinements in screening 
and ultimately to reduce short and long term cardiovascular 
morbidity and mortality that patients with cancer are exposed to. 
Future screening for patients with cardiotoxicity will likely involve a 
multi-modality approach for improved risk stratification, prog-
nostication and tailoring of individual chemotherapeutic regimens.
Conflict of interest: none declared.
FIGURE 7: Short-axis mid-ventricular late gadolinium enhance-
ment image in a patient with trastuzumab-induced cardiomyopathy 
demonstrating mid-myocardial and subepicardial lateral wall 
delayed enhancement. Reproduced with permission from.(51)
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